Despite the higher overall survival demonstrated by FOLFIRINOX study, the first option for first-line treatment of patients with metastatic pancreatic cancer is still gemcitabine.
Reasons for this preference may involve the array of drugs approved to treat pancreatic cancer in Brazil, patient's performance status or lack of awareness about the newest schemes.
In second line, however, the trend appears to be shifting towards the OFF regimen.
CONCLUSION
This is a descriptive, retrospective study in patients with metastatic pancreatic cancer.
Data was extracted from Evidências _ Kantar Health database of claims, which comprises 46 private health insurance companies covering nearly 10 million lives, of which 4 million are in the oncology sector.
Data extraction was performed from January/2014 to December/2014.
After patient de-identification, information on demographics, type of treatment, number of cycles was retrieved and tabulated.
The most reported treatments according to their generic name were defined as the pattern of care.
METHODOLOGY
Data were collected from a claims database, which means these were requests for patient treatments. Some patients might not have taken a cycle due to other issues such as neutropenia, progression, etc.
Length of treatment is limited to the last solicitation input on the system for a given patient, since we do not have access to data on the patients' deaths. 
LIMITATIONS

RESULTS
We identified 102 patients diagnosed with pancreatic cancer. 39 were excluded, since the disease was not metastatic.
63 patients with metastatic pancreatic cancer were included. As for geographic region, 17 patients were from the Southeast, 10 from Center-West, 12 From Northeast, and 24 from the South Region.
Mean age was 63.5 years and mean weight 66.7 kilograms (see Table 1 ). The most common regimen in first-line treatment was gemcitabine monotherapy (58.5%); followed by FOLFIRINOX (37.7%) and OFF (1.88%) (see Figure 2) .
In second line, OFF was the most prescribed therapeutic scheme (80%), followed by gemcitabine monotherapy (10%) and FOLFORINOX (10%) (see Figure 3) .
Most patients in first-line received 3 cycles of treatment (43.4%), 32.1% received 6 cycles, 13,2% received 12 cycles and 11,3% received variable number of cycles.
Patients in second-line received either 3 cycles (30%) or 6 cycles (70%).
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Since pancreatic cancer has a low incidence, often a delayed diagnosis and poor prognosis 1 it is crucial to know how these patients are being treated in the real world. We did not find any study similar to this one, published in the Brazilian literature.
Differently from other neoplasms, there are not many therapeutic options for pancreatic cancer. In first-line, the option with best clinical outcomes is FOLFORINOX 2 although it comes with considerable toxicity, which limits its application in patients with poor performance status (not always the case for those diagnosed with pancreatic cancer).
Our findings show that most patients are treated with gemcitabine monotherapy in first-line, despite the treatment's lower progression-free survival rates when compared to other schemes. The motives for this predilection among Brazilian oncologists are not clear. Some possible explanations are:
Lack of knowledge on other chemotherapy regimens and their survival rates Drugs like irinotecan and oxaliplatin (which are part of the FOLFORINOX regimen) are not approved in Brazil to treat pancreatic cancer and that would lead healthcare insurance companies to deny any such requests Due to late diagnosis, patients would present really low performance status and would not be eligible for more regimens with higher toxicity rates There are other combinations studied in the literature that have somewhat better survival rates in first-line, such as gemcitabine plus nanoparticulate paclitaxel
